Literature DB >> 15726656

Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.

Alan Lee Rothman1, Chihiro Morishima, Herbert L Bonkovsky, Stephen J Polyak, Ranjit Ray, Adrian M Di Bisceglie, Karen L Lindsay, Peter F Malet, Ming Chang, David R Gretch, Daniel G Sullivan, Atul K Bhan, Elizabeth C Wright, Margaret James Koziel.   

Abstract

The relationships among host immune and viral factors and the severity of liver disease due to hepatitis C virus (HCV) are poorly understood. Previous studies have focused on individual components of the immune response to HCV, often in relatively small numbers of patients. We measured HCV-specific lymphoproliferation (LP), intrahepatic cytotoxic T lymphocyte (CTL), and neutralizing antibody (NA) responses and HCV quasispecies (QS) diversity and complexity in a large cohort of subjects with advanced liver fibrosis (Ishak stages 3-6) on entry into the HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial. We correlated LP, CTL, NA, and QS results with clinical characteristics, including serum alanine aminotransferase (ALT), HCV RNA level, HCV genotype, and hepatic histopathology. LP, CTL, and NA responses were detected in 37%, 22%, and 22% of subjects tested, respectively. The only association that was statistically significant was higher mean serum ALT values in patients with detectable HCV-specific CTL responses (P = .03). In conclusion, immune responses to HCV and viral diversity showed little relationship to clinical or histological features at a single time point in this selected population of patients with advanced chronic hepatitis C for whom prior interferon treatment had failed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726656     DOI: 10.1002/hep.20581

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  Response of combination therapy on viral load and disease severity in chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha H Das; Premashis Kar
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 3.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 4.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

5.  Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.

Authors:  Bing-Shui Xiu; Xiao-Yan Feng; Jing He; Guo-Hua Wang; Xiang-Ying Zhang; He-Qiu Zhang; Xiao-Guo Song; Kun Chen; Shi-Gan Ling; Cui-Xia Zhu; Lai Wei; Hui-Ying Rao
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

6.  Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha-H Das; Premashis Kar
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

7.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

8.  Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Authors:  Ranjit Ray; Keith Meyer; Arup Banerjee; Arnab Basu; Stephen Coates; Sergio Abrignani; Michael Houghton; Sharon E Frey; Robert B Belshe
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

9.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 10.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.